We sought to identify proteins secreted by the human placenta into the maternal and fetal circulations. Blood samples from the maternal radial artery and uterine vein and umbilical artery and vein were obtained during cesarean section in 35 healthy women with term pregnancy. Slow off-rate modified aptamer (SOMA) proteinbinding technology was used to quantify 1310 known proteins. The uteroplacental and umbilical venoarterial concentration differences were calculated. Thirty-four proteins were significantly secreted by the placenta into the maternal circulation, including placental growth factor, growth/differentiation factor 15, and matrix metalloproteinase 12. There were 341 proteins significantly secreted by the placenta into the fetal circulation. Only 7 proteins were secreted into both the fetal and maternal circulations, suggesting a distinct directionality in placental protein release. We examined changes across gestation in the proteins found to be significantly secreted by the placenta into the maternal circulation using serial blood samples from healthy women. Among the 34 proteins secreted into the maternal circulation, 8 changed significantly across gestation. The identified profiles of secreted placental proteins will allow us to identify novel minimally invasive biomarkers for human placental function across gestation and discover previously unknown proteins secreted by the human placenta that regulate maternal physiology and fetal development.-Michelsen, T. M., Henriksen, T., Reinhold, D., Powell, T. L., Jansson, T. The human placental proteome secreted into the maternal and fetal circulations in normal pregnancy based on 4-vessel sampling. FASEB J. 33, 2944-2956 (2019). www.fasebj.org
The human placenta is a formidable endocrine organ secreting a wide array of proteins (including hormones, cytokines, and growth factors), glycoproteins, and steroid hormones. Many of these secretory products are synthesized by the syncytiotrophoblast, which expresses the molecular machinery for protein biosynthesis (1) . According to the Human Protein Atlas, transcriptomic analyses show that 70% of more than 19,000 human proteins are expressed in the placenta. Among these, 354 genes show an elevated expression in the placenta compared with other tissue types, and most encode for secreted proteins (2, 3) . Several proteins are known to be secreted by the placenta into the maternal blood, including human chorionic gonadotropin (4, 5) human placental lactogen (6) , human growth hormone variant or placental growth hormone (6) (7) (8) , leptin (9) , corticotropinreleasing hormone (10) , placental growth factor (PlGF) (11) and pregnancy-associated plasma protein A (12) . Some of these proteins are believed to play a critical role in the maternal physiologic adaptations to pregnancy. In addition, emerging evidence suggests that placentally derived factors are critical for normal fetal development. For example, serotonin synthesized by the placenta in midgestation is critical for the development of the forebrain in mice (13) , and maternal inflammation in this animal model disrupts fetal neurodevelopment mediated by increased placental secretion of serotonin into the fetus (14) . The identity of proteins secreted by the human placenta remains to be fully established.
Abnormal placental function contributes to the development of important pregnancy complications such as intrauterine growth restriction and preeclampsia (15) (16) (17) (18) . To identify relevant placental biomarkers for early prediction of these pregnancy complications, a range of factors believed to be derived from the fetus and the placenta, including proteins, exosomes, microvesicles, and fetal cell free DNA and miRNA, measured in maternal blood, have been assessed (19, 20) . Despite these efforts, recent systematic reviews and meta-analyses suggest that none of the currently available biomarkers predicts intrauterine growth restriction with sufficient sensitivity to be used in routine clinical practice (21) . One reason for this limited success may be that the relationship between the presence of these factors in the maternal circulation and placental function remains elusive. More recently, proteomics discovery approaches have been used to identify biomarkers in maternal blood for pregnancy disease and as proxies for placental function (19) . However, these approaches have limitations, including the lack of information on the extent to which the identified factors originate from the placenta, as opposed to maternal tissues.
Traditional proteomics in serum and plasma samples have some crucial shortcomings, including the need for removal of high-abundance proteins to analyze otherwise obscured low-abundance proteins. The slow off-rate modified aptamer (SOMA) protein-binding technology is a proteomic platform with very high sensitivity and dynamic range, thereby circumventing some of the major problems with traditional proteomics in plasma (22) .
Our current understanding of which proteins the human placenta secretes specifically into the maternal circulation is largely based on studies of human placental explants, isolated primary human trophoblasts, and immortalized trophoblast cell lines (1) . In vivo studies in women have been limited by the relative inaccessibility of the uteroplacental circulation, making it difficult to obtain the blood samples needed for accurate assessment of concentration gradients between the uterine vein and artery.
To address this essential problem, we have developed a novel approach, 4-vessel sampling ( Fig. 1) , allowing collection of blood samples from the human placental circulation in vivo (23, 24) . These samples enable us to measure proteins, metabolites, and metabolic regulators in both the incoming and outgoing vessels (arteriovenous differences) on the maternal and fetal sides of the placenta. Besides providing novel physiologic data on placental uptake and release of multiple compounds, our 4-vessel sampling method also offers an unprecedented opportunity to identify proteins specifically secreted into the maternal circulation that can be used as biomarkers of placental function across gestation.
To identify novel proteins specifically secreted by the human placenta into the maternal and fetal circulations, we collected blood samples from the maternal radial artery and uterine vein and the umbilical artery and vein during cesarean section in 35 healthy women with normal term pregnancies. Proteins (n = 1310) were measured with a proteomic platform (SomaLogic, Boulder, CO, USA), and concentration differences across the uteroplacental and umbilical circulations were determined. We subsequently examined changes across gestation in the proteins significantly secreted by the placenta into the maternal circulation in first-, second-, and third-trimester maternal blood samples from 8 healthy pregnancies. To elucidate potential functional roles of these proteins, we performed network protein analyses and mapping of protein interactions.
MATERIALS AND METHODS

Four-vessel sampling
Thirty-five healthy women undergoing planned cesarean section at Rikshospitalet after normal term pregnancies were enrolled. Prelabor cesarean delivery was performed in patients under spinal anesthesia. We sampled from the maternal radial artery and uterine vein on the anterolateral surface of the uterus immediately before uterine incision. After delivery of the infant and before detachment of the placenta, we sampled from the umbilical artery Figure 1 . The 4-vessel sampling method. Blood samples were collected during cesarean section from the maternal radial artery and uterine vein and from the umbilical artery and vein. and vein. The method has been previously described in detail elsewhere (23, 24) . The blood samples were transferred immediately to EDTA vacutainers (Greiner Bio-One, Kremsmunster, Austria), kept on ice, and centrifuged within 30 min (6°C, 2500 g, 20 min). The plasma was stored at 280°C. Maternal clinical data were collected at enrollment.
The participants were enrolled after written informed consent by using a protocol approved by The Regional Committee for Medical and Health Research Ethics of Southeast Norway (S-07174a and 2419/2011).
The Denver Baby Blanket cohort
We examined changes across gestation in the proteins significantly secreted by the placenta into the maternal circulation using first-, second-, and third-trimester maternal plasma samples from 8 women in the Denver Baby Blanket cohort (Baby Blanket). Women providing plasma from the Baby Blanket cohort were drawn from a sample of 1128 women who presented for prenatal care at or before 23 wk gestation and planned to deliver their infants at the University of Colorado Hospital from 2011 through 2013. Plasma samples were drawn once per trimester, when possible, and all women were observed for the remainder of their pregnancies and for birth outcomes. Plasma samples were divided into aliquots and stored at 280°C in a Biorepository at the University of Colorado Hospital. Details of the cohort have been described by Lynch et al. (25) .
Proteomics
The University of Colorado Anschutz Medical Campus Genomics and Microarray Core used the SOMAscan platform previously described (22, 26, 27) to quantify protein levels. The basis of the approach is that each of the 1310 individual proteins measured has its own binding reagent made of modified DNA and referred to as a modified aptamer. Each sample of plasma from the 4 different vessels was incubated with the mixture of modified aptamers, and aptamer-protein complexes were made. Aptamer reagents were captured on a bead and equilibrated with a biologic sample. After equilibration, unbound proteins were removed. Complexes were released from the bead, and fast off-rate complexes were dissociated. The remaining proteins were captured on a second bead, removing unbound aptamer reagents. The complexes were noncovalent, and aptamer reagents were therefore released under denaturing conditions. After the modified aptamers were eluted from the target protein, the fluorescently labeled modified aptamers were directly quantified on a hybridization array (Agilent Technologies, Santa Clara, CA, USA). Calibrators were included so that the degree of fluorescence was a quantitative reflection of protein concentration.
Secreted and absorbed proteins
We assumed similar blood composition in the radial and uterine arteries. The uteroplacental venoarterial (uterine vein minus radial artery) and umbilical venoarterial (umbilical vein minus umbilical artery) concentration differences were calculated with log 2 -transformed protein concentrations. Thus, positive concentration differences represent secretion from the placenta into the maternal or fetal circulation, whereas a negative concentration difference represents placental uptake.
Correction for water shift in the placenta
Because of the low net water movement between the maternal, placental, and fetal compartments, there may be a change in blood water content between the maternal artery and vein and the umbilical artery and vein. To account for this water shift, we corrected the protein concentrations in the uterine vein and the umbilical artery as described by Holm et al. (28) .
Statistical methods
Four-vessel sampling
The SOMA scan data were normalized and calibrated according to standard workflow (hybridization normalization, late scaling, and calibration). On both the fetal and maternal side, the vein: artery ratios of the SOMAscan signals were log 2 -transformed to obtain data that were more normally distributed and to facilitate statistical analysis. Each sample was run twice, and we used the average log 2 ratio.
All statistical analyses were performed with R Statistical Software (29) . We performed 2-sided Student's t tests on the log 2ratios of each of the 1310 proteins on the fetal side, which corresponds to a paired Student's t test of the log 2 -transformed values. Multiple testing adjustment according to Benjamini-Hochberg (30), to control the false discovery rate, was performed with the R function p.adjust, and an adjusted value of P , 0.05 was considered significant.
We used NetworkAnalyst (www.networkanalyst.ca) to perform data analyses with protein-protein networks on secreted and absorbed placental proteins. NetworkAnalyst is a web-based application designed to address statistical and visualization challenges during meta-analysis of complex gene expression and protein data sets (31) . We uploaded separate protein sets based on proteins that were secreted into the maternal circulation and secreted and absorbed on the fetal side of the placenta. We used UniProt Knowledge Base (UniProtKB) IDs (https://www.uniprot. org/) to identify the proteins. Some SomaLogic proteins are protein families or proteins composed of subunits, resulting in multiple UniProtKB IDs. Moreover, some UniProtKB IDs map to different SomaLogic IDs. We used all unique UniProtKB IDs as the reference/background list (all SomaLogic proteins) and as the list to be analyzed (secreted and absorbed proteins, respectively). There were 1318 proteins in our reference list, and 335 proteins were mapped in our list of secreted proteins on the fetal side. Similarly, of the absorbed proteins on the fetal side, 217 proteins were mapped. Finally, 36 of the secreted proteins on the maternal side were mapped. We used the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; https://string-db.org/) interactome with medium to high confidence, as described by Szklarczyk et al. (32) and first-order networks.
Analysis of the Denver Baby Blanket cohort
We determined changes in log 2 -transformed protein abundance across gestation in the proteins significantly secreted by the placenta into the maternal circulation by using first-, second-and third-trimester maternal blood samples from 8 women in the Denver Baby Blanket cohort (Baby Blanket). Differences between second and first trimester (D1) and between the third and second trimester (D2) were determined, as were d1 and d2, defined as the population differences between the trimesters. Subsequently, Hotelling's T 2 test was used to test which proteins change over time-that is, we tested if (d1, d2) = (0, 0). We adjusted for multiple testing according to Benjamini-Hochberg using the R function p.adjust.results.
RESULTS
Demographics
The mean age of the participants in the 4-vessel cohort was 36.1 (SD 4.7) yr, and 10 of 35 women were primiparous ( Table 1) . Maternal early pregnancy body mass index (BMI) ranged from 17 to 39, with a mean in the normal range. All women had normal pregnancies and did not use any medications. All study subjects were scheduled for elective cesarean delivery and gave birth at mean gestational age 39.2 (0.4) wk. Mean birth weight was 3560 (461) g, considered normal by Norwegian population averages, and mean placenta weight was 616 (116) g, well within the normal range for human term pregnancies. In the longitudinal analysis, consisting of samples from the Baby Blanket cohort, mean gestational age was 39.4 (0.7) wk ( Table 2 ). The women had normal early-pregnancy BMI, and mean birth weight was 3212 (128) g.
Proteomics analysis
The SomaLogic proteomic analyses indicated that 34 proteins were released by the placenta into the maternal circulation based on significantly higher uterine vein levels compared with the radial artery ( Table 3 ). In addition, we found that 341 proteins were released into the fetal circulation ( Supplemental Table S1 ) based on significantly higher levels in the umbilical vein compared with the umbilical artery. Among the 1310 proteins analyzed, only 7 were secreted into both the maternal and fetal circulations ( Table 4 ). Nine proteins were absorbed by the placenta on the maternal side (radial artery . uterine vein) ( Supplemental Table S2 ), and 210 proteins were taken up by the placenta on the fetal side (umbilical artery . umbilical vein) (data not shown).
Protein-protein interaction visualization
We used NetworkAnalyst to map protein-protein interactions based on published networks by Szklarczyk et al. (32) .
The NetworkAnalyst mapping of protein-protein interaction among proteins significantly secreted by the placenta into the maternal circulation ( Fig. 2) , showed that drebrin-like protein (150 connections), heat shock protein b1 (101 connections), annexin A2 (52 connections), secreted frizzled-related protein 1 (47 connections), annexin A1 (46 connections), glypican 3 (41 connections), frizzledrelated protein (38 connections), and Dickkopf-related protein 1 (37 connections) were the proteins with the most connections to other proteins.
We used NetworkAnalyst to map the proteins significantly secreted into the fetal circulation ( Fig. 3) . Proteins with the highest order of connections to other proteins were epidermal growth factor receptor (213 connections), neurogenic locus notch homolog protein (NOTCH) 1 (161 connections), tyrosine-protein Janus kinase (JAK) 2 (124 connections), VEGF receptor 2 (92 connections), platelet-derived growth factor receptor b (88 connections), and insulin-like growth factor 1 receptor (82 connections).
For the proteins significantly taken up by the placenta from the fetal circulation ( Fig. 4) , the proteins with the highest order of connections to other proteins were ribosomal protein S27a (197 connections), cyclindependent kinase-1, ribosomal protein S3 (136 connections), ubiquitin B (132 connections), estrogen receptor 1 (123 connections), Jun proto-oncogene-AP-1 transcription factor subunit (122 connections), SMAD family member 3 (112 connections), and ribosomal protein S3a (102 connections).
Changes in the maternal placental secretome across gestation
We studied all 34 proteins significantly secreted by the placenta into the maternal circulation across gestation in our longitudinal cohort ( Table 5 ). Based on measurements from all 3 trimesters and after adjustment for multiple testing, we found significant changes in protein secretion across gestation for inhibin b A chain (increase), Kunitztype protease inhibitor 2 (increase), PlGF (increase), IGFbinding protein 7 (decrease), urokinase-type plasminogen activator (increase), growth/differentiation factor (GDF) 15 (increase), macrophage metalloelastase [matrix metalloproteinase (MMP)-12 (decrease) and glypican 3 (increase)], as illustrated in Fig. 5 .
DISCUSSION
In this study, we report for the first time the human placental secretome based on a unique blood sampling method and a novel proteomic approach. Our results indicate that the placenta secretes proteins into both the maternal and fetal circulations and that there is a remarkable directionality in placental protein release. We identify a large number of proteins previously unknown to be secreted by the human placenta into the maternal or fetal circulation. These proteins may regulate fetal development and maternal physiology, and proteins secreted into the maternal circulation represent candidates for novel biomarkers of placental function.
The placenta secreted 34 proteins into the maternal circulation. To the best of our knowledge, this is the first direct evidence of proteins specifically secreted into the maternal circulation by the human placenta in vivo. Placental origin of proteins present in the maternal circulation has been established indirectly by evidence of increased levels in pregnancy and rapid decrease in the abundance of the protein in the maternal circulation after delivery. Alternatively, the demonstration of secretion of proteins from human placental explants, isolated primary human trophoblasts, and immortalized trophoblast cell lines have been used to support that proteins in the maternal circulation are of placental origin (1) .
PlGF is an important regulator of maternal endothelial function. Using the same approach to collect uterine vein and maternal radial artery blood samples as in the current study and measuring PlGF by ELISA, we have previously reported that PlGF is secreted by the placenta into the maternal circulation, in both normal and preeclamptic pregnancies (23) . Consistent with that report, PlGF was also significantly secreted into the maternal circulation in the present study, supporting the validity of our approach. In agreement with the literature (33), maternal PlGF levels increased from the first to the second trimester of pregnancy in our longitudinal cohort, and the concentrations of PlGF in the maternal circulation subsequently declined slightly toward term.
For most of the proteins identified as secreted by the placenta into the maternal circulation in the current study, the placental origin was previously unknown. GDF-15 was secreted by the placenta and showed a significant increase in concentration across gestation. Previous studies demonstrated that circulating concentrations of GDF-15 were increased in women who later developed preeclampsia, which correlated with increased placental GDF-15 mRNA levels (34) . Maternal GDF-15 levels have been reported to increase 10-fold across gestation (35) , a finding that was replicated in the present study. We also found placental secretion of MMP-12 into the maternal circulation. MMP-12 is expressed by trophoblasts in the first trimester placental bed and is involved in the remodeling of spiral arteries (36) . Lower expression of MMP-12 mRNA has been detected in placentas of women who developed preeclampsia (37) . GDF-15 and MMP-12 are examples of proteins that may increase our understanding of how the placenta influences maternal physiology during pregnancy, and they are also potential candidates for biomarkers of placental function.
Among the proteins shown to be significantly secreted by the placenta into the maternal circulation, there are some receptors. Although the secretion of soluble receptors from the trophoblast or the human placenta has not been studied systematically, placental secretion of receptors has been reported previously, the most well-known example being the soluble VEGF receptor-1 (soluble fmslike tyrosine kinase 1, sFlt-1). This receptor is a potent circulating antagonist to VEGF and placental growth factor and has been implicated in the pathophysiology of preeclampsia given the increased placental secretion and circulating maternal levels in this disease (23, 38) . In addition, secretion of soluble receptors is not unique to the placenta. For example, sFlt-1 is secreted by endothelial cells (39) and monocytes (40) .
One of the receptor proteins secreted by the placenta into the maternal circulation was annexin A2. Annexin A2 is a cell surface coreceptor for plasminogen and its activator, tissue-type plasminogen activator (41) . Annexin A2 shows higher mRNA expression and higher protein levels in maternal blood in normal pregnancies than in pregnancies complicated by preeclampsia (41) . Soluble annexin A2 in blood has been shown to reduce thrombus formation in rat carotid arteries and has proven fibrinolytic capabilities in a rat stroke model (42, 43) . The significant release of annexin A2 into the maternal circulation confirms that annexin A2 is released from the placenta in normal pregnancies. It also indicates that annexin A2 may be a modulator of normal pregnancy physiology, given its role in plasmin homeostasis, and the fact that annexin A2 may play a pathophysiological role in the development of preeclampsia is consistent with the possibility that annexin A2 can be used as a biomarker of placental function. Two other receptors secreted by the placenta into the maternal circulation were secreted frizzled related protein (SFRP)1 and -3. SFRPs are structurally similar to the frizzled family of membrane-anchored wingless integrated (Wnt) receptors, but lack the transmembrane and intracellular components necessary for signal transduction (44) . It has been proposed that SFRPs inhibit the WNT pathway by binding to either the WNT ligand or frizzled receptor (45) . Increased placental expression of SFRPs has been linked to reduced placental growth and intrauterine growth restriction (44) . Recently, increased SFRP1 mRNA expression was reported to be linked to decreased placental and fetal growth in smokers (46) .
We found significant changes in maternal concentration across gestation for 8 of the 34 proteins secreted by the placenta into the maternal circulation. Changes across gestation in the maternal concentrations of a placentaderived protein are not critical for its usefulness as a biomarker or read-out of placental function; however, the pattern of change must be known because prediction models must allow for these changes. Romero and coworkers (47) used the SomaLogics platform to study maternal plasma proteomic profiles across gestation, and documented that there are marked gestational changes in Figure 2 . Protein-protein interactions among proteins secreted by the placenta into the maternal circulation, analyzed with NetworkAnalyst. Protein-protein interaction map with proteins significantly secreted from the placenta into the maternal circulation. First-order network based on networks published by Szklarczyk et al. (32) . ANXA, annexin A; CXB, creatine kinase B; DBNL, drebrin-like protein; DKK1, Dickkopf WNT signaling pathway inhibitor 1; FRZB, frizzled-related protein; GPC3, glypican 3; HSPB1, heat shock family B (small) member 1; and SFRP1, secreted frizzled-related protein 1.
the plasma proteome of normal pregnancy. The authors suggested that such information is important to understand the physiology of pregnancy and to aid in the development of biomarkers. Their study did not include 4vessel sampling and therefore could not determine proteins specifically secreted by the placenta. Whereas Romero and collaborators studied changes across gestation in 1125 proteins, we analyzed 1310 proteins and determined the longitudinal changes across gestation of 34 proteins specifically secreted by the placenta into the maternal circulation. The results are therefore not directly comparable. However, 5 of the 8 placenta-specific proteins (placental growth factor, urokinase-type plasminogen activator, inhibin b A chain/activin A, MMP-12, and glypican 3) that showed significant changes across gestation in the current study paralleled the gestational changes reported by the previous study, although the latter 2 did not show significant changes after adjusting for multiple testing in our data set. The sixth protein (growth differentiation factor 15) was not part of the SOMAscan platform used by Romero and coworkers (47) . For the 26 remaining proteins, the results from the 2 studies were in complete agreement. The level of reproducibility between the 2 studies is therefore high and supports the validity of our approach.
Little is known about protein secretion from the placenta to the fetus. We identified 341 proteins that were significantly secreted by the placenta into the fetal circulation, and it is plausible that many of these proteins have important roles in regulating fetal development. This finding may be of critical importance for infants born preterm and therefore prematurely deprived of the placental proteome, which may be necessary to promote normal maturation of, for example, the brain and lungs. If so, the key to further improve the management of preterm infants may lie in identifying the specific functions of the proteins secreted by the human placenta into the fetal circulation with the exciting prospect of supplementation Figure 3 . Protein-protein interactions among proteins secreted by the placenta to the fetal circulation, according to NetworkAnalyst. Protein-protein interaction map with proteins significantly secreted from the placenta into the fetal circulation. First-order network based on networks published by Szklarczyk et al. (32) . CDH1, cadherin 1; EGFR, epidermal growth factor receptor; ERBB3, Erb-b2 receptor tyrosine kinase 3; FGFR1, fibroblast growth factor receptor 1; FN1, fibronectin 1; IGF1R, insulin-like growth factor 1 receptor; INSR, insulin receptor; ITGB1, integrin subunit-b1; JAK2, Janus kinase 2; KDR, kinase insert domain receptor; MED1, mediator complex subunit 1; MET, MET proto-oncogene, receptor tyrosine kinase; NOTCH1, Neurogenic locus notch homolog protein; PDGFRA, platelet-derived growth factor receptor a; PDGFRB, platelet-derived growth factor receptor b; SHH, sonic hedgehog; and UBC, ubiquitin C.
of selected proteins or their analogs to improve outcome in preterm infants.
The protein secreted by the placenta into the fetal circulation with second most connections in our network analysis was NOTCH1. NOTCH1 is detected in extravillous trophoblast progenitors and is believed to be a key regulator promoting development of the human extravillous trophoblast lineage (49) . In addition, NOTCH1 may be involved in mesoderm development, somite formation, and neurogenesis (50, 51) . This finding suggests that NOTCH1 plays a role in fetal development in addition to its documented role in placental development.
The tyrosine protein kinase JAK2 was also secreted into the fetal circulation and was the protein with the third most interactions in our network analysis. JAK2 is known to be involved in development of mammary epithelium during pregnancy (52) . In addition, Parganas et al. (53) showed that in JAK2-deficient mice, the mutation caused embryonic lethality because of the absence of definitive erythropoiesis. In the JAK2-deficient mice, fetal liver myeloid progenitors failed to respond to erythropoietin, thrombopoietin, IL-3, or granulocyte/macrophage colonystimulating factor. Based on the findings in our study, it is possible that fetal erythropoiesis is dependent on JAK2 secreted by the placenta.
We found a placental uptake of VEGF-A from the maternal circulation. The VEGF-A gene is expressed in the placenta, but also in endothelial cells, vascular smooth muscle cells, and various other tissues (2) . VEGF-A belongs to the VEGF family, promotes vasculogenesis and CSNK2A1, casein kinase 2a1; EIF4A3, eukaryotic translation initiation factor 4A3; ESR1, estrogen receptor 1; HIF1A, hypoxiainducible factor 1, subunit a; HNRNPA2B1, heterogeneous nuclear ribonucleoprotein A2/B1; JUN, Jun proto-oncogene, AP-1 transcription factor subunit; MAP3K7, mitogen-activated protein kinase 7; PES1, pescadillo ribosomal biogenesis factor 1; PSMA6, proteasome subunit a6; RB1, RB transcriptional corepressor 1; RPS3, ribosomal protein S3; RPS3A, ribosomal protein S3A; RPS7, ribosomal protein S7; RPS27a, ribosomal protein S27a; SKP1, S-phase kinase associated protein 1; UBB, ubiquitin B; UBC, ubiquitin C; UBE2I, ubiquitin conjugating enzyme E2 I; and VAV1, vav guanine nucleotide exchange factor 1.
angiogenesis, and exerts its action through the VEGF receptor 1 (Flt-1) and VEGF receptor 2 (KDR) (54) . The lower concentration of VEGF-A in the uterine vein as compared to the radial artery indicates that the maternally derived VEGF-A binds to the Flt-1 or KDR receptors in the placenta, possibly on the syncytiotrophoblast microvillus plasma membrane, and subsequently is internalized and degraded. KDR receptors seem to be expressed in association with endothelial cells in the human placenta (55) . An in vitro study demonstrated that cytotrophoblasts internalize VEGF-A, lower levels of VEGF-A lead to decreased adhesion and increased apoptosis, and the VEGF family contributes to cytotrophoblast cell survival (56) .
Strengths of the present study include the 4-vessel sampling method, which provides a novel insight into placental secretion into both the maternal and fetal circulations. The SOMAscan method has several advantages, including high-affinity binding to low-abundance proteins.
The study has some limitations. First, the 4-vessel sampling method was based on concentration differences between maternal and fetal arteries and veins. On the maternal side, we cannot distinguish between proteins secreted by the trophoblast, the decidua, and the myometrium. However, because the fraction of uteroplacental blood flow that supplies the myometrium is small, the uteroplacental venoarterial concentration difference represents predominantly placental secretion or uptake. On the fetal side, we cannot differentiate contributions from the trophoblast and the fetal placental capillary endothelium. Second, the SOMAscan platform analyzes 1,310 First to second percentage change, percentage change from first trimester to second trimester; second to third percent change, percentage change percent from second trimester to third trimester. a Based on Hotelling's T 2 test of differences in log 2 -transformed protein concentrations between the first and second trimester and the second and third trimester. b Adjusted according to Benjamini-Hochberg.
proteins at the moment, whereas close to 20,000 proteins are expressed in the human body (2) . We therefore cannot determine whether any proteins outside the SOMAscan platform are secreted by the placenta into the maternal or fetal circulations. In addition, proteins represented on the platform have been selected to include human proteins Figure 5 . Significant changes in placental protein secretion across gestation for proteins secreted into the maternal circulation. Changes in protein abundance across gestation in the proteins significantly secreted by the placenta into the maternal circulation using first-, second-, and third-trimester blood samples from 8 women in the Baby Blanket cohort. associated with disease, and the aptamer technology therefore lacks the unbiased discovery approach character.
The identified placenta-specific proteomic profiles will allow us to identify novel minimally invasive placental biomarkers across gestation and previously unknown proteins secreted by the placenta and regulating maternal physiology and fetal development. This work will help us better understand the functions of the human placenta in normal and complicated pregnancies. 
